12 October 2021 : Original article
Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
Chengxin Luo12CDE, Qingrong Li12B, Xi Li
3B, Guixian Wu12B, Xiangtao Huang12B, Yali Zhang12B, Yanni Ma12B, Mingling Xie12B, Yanni Sun 12B, Yarui Huang12B, Zhen Huang12B, Shuangnian Xu12AEG*, Jieping Chen12AEG
DOI: 10.12659/AOT.933365
Ann Transplant 2021; 26:e933365
Table 1 Characteristics of included patients.
| Characteristic | Total | High albumin (≥37 g/L) | Low albumin (<37 g/L) | P |
|---|---|---|---|---|
| Gender | 0.409 | |||
| Male | 71 (62.8%) | 60 (61.2%) | 11 (73.3%) | |
| Female | 42 (37.2%) | 38 (38.8%) | 4 (26.7%) | |
| Age | 0.128 | |||
| >60 years | 10 (8.8%) | 7 (7.1%) | 3 (20.0%) | |
| ≤60 years | 103 (91.2%) | 91 (92.9%) | 12 (80.0%) | |
| BMI | 0.355 | |||
| <18.5 | 11 (10.1%) | 11 (11.7%) | 0 | |
| ≥18.5 | 98 (89.9%) | 83 (88.3%) | 15 (100%) | |
| Disease | 0.316 | |||
| HL | 14 (12.4%) | 14 (14.3%) | 0 | |
| NHL | 99 (87.6%) | 84 (85.7%) | 15 (100%) | |
| B-NHL | 80 (70.8%) | 66 (78.6%) | 14 (93.3%) | |
| T-NHL | 15 (13.3%) | 14 (16.7%) | 1 (6.7%) | |
| NK/T-NHL | 4 (3.5%) | 4 (4.8%) | 0 | |
| ECOG PS | 0.575 | |||
| 0–1 | 69 (61.1%) | 61 (62.2%) | 8 (53.3%) | |
| 2–3 | 44 (38.9%) | 37 (37.8%) | 7 (46.7%) | |
| Ann Arbor stage | 0.732 | |||
| I–II | 22 (19.5%) | 20 (20.4%) | 2 (13.3%) | |
| III–IV | 91 (80.5%) | 78 (79.6%) | 13 (86.7%) | |
| B symptoms | 0.568 | |||
| Absent | 73 (64.6%) | 62 (63.3%) | 11 (73.3%) | |
| Present | 40 (35.4%) | 36 (36.7%) | 4 (26.7%) | |
| IPI risk | 0.117 | |||
| Low | 40 (35.4%) | 37 (37.8%) | 3 (20.0%) | |
| Low-intermediate | 36 (31.9%) | 32 (32.7%) | 4 (11.1%) | |
| High-intermediate | 22 (19.5%) | 19 (19.4%) | 3 (20.0%) | |
| High | 15 (13.3%) | 10 (10.2%) | 5 (33.3%) | |
| LDH level | 0.024* | |||
| Normal | 69 (61.1%) | 64 (65.3%) | 5 (33.3%) | |
| Elevated | 44 (38.9%) | 34 (34.7%) | 10 (66.7%) | |
| Bone marrow involvement | 0.053 | |||
| Yes | 12 (10.6%) | 8 (8.2%) | 4 (26.7%) | |
| No | 101 (89.4%) | 90 (91.8%) | 11 (73.3%) | |
| Months from diagnosis to ASCT (median, range) | 8 (3–99) | 8 (3–99) | 14 (5–39) | 0.125 |
| Prior regimens | 0.127 | |||
| <5 | 78 (69.0%) | 70 (71.4%) | 8 (53.3%) | |
| 5–10 | 30 (26.5%) | 25 (25.5%) | 5 (33.3%) | |
| ≥10 | 5 (4.4%) | 3 (3.1%) | 2 (13.3%) | |
| Disease status | 0.026* | |||
| CR | 54 (47.8%) | 51 (52.0%) | 3 (20.0%) | |
| PR/NR | 59 (52.2%) | 47 (48.0%) | 12 (80.0%) | |
| Conditioning regimens | 0.054 | |||
| BEAM | 23 (20.4%) | 20 (20.4%) | 3 (20.0%) | |
| BEAC | 31 (27.4%) | 28 (28.6%) | 3 (20.0%) | |
| CBV | 30 (26.5%) | 29 (29.6%) | 1 (6.7%) | |
| CHOP-like | 27 (23.9%) | 20 (20.4%) | 7 (46.7%) | |
| Others | 2 (1.8%) | 1 (1.0%) | 1 (6.7%) | |
| Mononuclear cell dose (×10/kg, median and range) | 5.27 (2.11–15.70) | 5.27 (2.11–15.70) | 5.14 (3.69–7.10) | 0.381 |
| Maintenance therapy | 0.366 | |||
| Yes | 42 (37.2%) | 38 (38.8%) | 4 (26.7%) | |
| No | 71 (62.8%) | 60 (61.2%) | 11 (73.3%) | |
| * ASCT – autologous stem cell transplantation; BEAC – carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM – carmustine, etoposide, cytarabine, and melphalan; BMI – body mass index; CHOP – cyclophosphamide, anthracycline, vincristine, and prednisone; CBV – cyclophosphamide, carmustine, and etoposide; CR – complete remission; ECOG PS – Eastern Cooperative Oncology Group performance status; HL – Hodgkin lymphoma; IPI – international prognostic index; LDH – lactate dehydrogenase; NHL – non-Hodgkin lymphoma; NR – no response; PR – partial remission. | ||||